JPRN-UMIN000006039招募中未知
Phase II study of perioperative mFOLFOX plus Panitumumab for stage III rectal cancer - perioperative mFOLFOX plus Panitumumab for stage III rectal cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Previous treatment of rectal cancer Multiple cancer and/or double cancer Any severe concurrent medical condition which would make it undesirable
研究者
相似试验
已完成
2 期
A phase II study of Perioperative FOLFOX4 plus Bevacizumab for initially unresectable Advanced Colorectal Cancer.colorectal cancerJPRN-UMIN000005572Japanese foundation for cancer research49
进行中（未招募）
1 期
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failureocally advanced rectal adenocarcinoma localized 0 - 16 cm from the anal verge with low risk of local failureMedDRA version: 20.0Level: LLTClassification code 10038052Term: Rectal carcinomaSystem Organ Class: 100000004864EUCTR2018-001356-35-DEniversity of Heidelberg550
已完成
不适用
Phase II study of first-line treatment by FOLFOXIRI+bevacizumab in patients with RAS mutant-type metastatic colorectal cancerColorectal CancerJPRN-UMIN000015152onprofit Organization Japan Clinical Cancer Research Organization60
已完成
2 期
Phase II study of FOLFOX4 in patients with advanced/recurrent colorectal cancer previously treated with 5FU (OGSG 0503)advanced/recurrent colorectal cancerJPRN-UMIN000000734OGSG50
进行中（未招募）
2 期
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach AdenocarcinomaGastro Esophageal Junction CancerAdenocarcinomaStomach CancerNCT03488667University of Kansas Medical Center40